Further, low-dose BTZ treatment markedly reduced Ang II-induced proinflammatory response and inhibited MMP activities, but simutaneously reversed the expression of differentiated markers and myocardin in AAA tissue. The gene discussed is AGT; the disease is triple-A syndrome.